SanegeneBio announced a global licensing agreement with Genentech, a member of the Roche Group, to advance one of its RNAi programmes based on its proprietary RNAi platform. Under the agreement, SanegeneBio grants Genentech exclusive worldwide rights to develop and commercialise the programme. SanegeneBio will be responsible for early development activities and Genentech will subsequently lead all future clinical development and commercialisation activities.

SanegeneBio's proprietary RNAi platform includes novel chemistries and delivery technologies that can be utilised to generate potential breakthrough siRNA medicines for multiple disease areas.

"Entering into this agreement with Genentech marks another important milestone for our innovative and differentiated RNAi chemistry and delivery platforms. We are delighted to work with a global scientific leader to continue delivering effective and life-changing therapies for patients worldwide," said Weimin Wang, PhD, Chief Executive Officer and Founder, SanegeneBio.

Under the terms of the agreement, SanegeneBio will receive an upfront payment of USD 200 million and will be eligible to receive development and commercialisation milestone payments, totaling up to USD 1.5 billion, as well as tiered royalties on potential future product sales.